DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Recombivax HB (Hepatitis B Vaccine (Recombinant)) - Published Studies

 
 



Recombivax HB Related Published Studies

Well-designed clinical trials related to Recombivax HB (Hepatitis B Vaccine)

Long-term efficacy of a hepatitis E vaccine. [2015]

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. [2011.07]

Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. [2011.06]

Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients. [2011.05]

Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination. [2011.05]

Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. [2011.04.13]

Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. [2011.04.05]

A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. [2011.04.01]

Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. [2011.04]

Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers. [2011.04]

Hepatitis B vaccination during pregnancy for preventing infant infection. [2011.03.16]

Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. [2011.03.09]

Low response to intradermal hepatitis B vaccination in incident hemodialysis patients. [2011.03]

Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. [2011.03]

Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. [2011.02.01]

Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. [2011.02.01]

Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. [2011.02]

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. [2010.12.20]

Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. [2010.11.29]

Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. [2010.11.15]

Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. [2010.11]

A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. [2010.10]

A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series. [2010.10]

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. [2010.09.11]

Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. [2010.08.23]

Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. [2010.08.02]

Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children. [2010.08]

Predictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program. [2010.08]

Seroprotection associated with infant vitamin A supplementation given with vaccines is not related to antibody affinity to Hepatitis B and Haemophilus influenzae type b vaccines. [2010.07.05]

Extra-high-dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial. [2010.07]

Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. [2010.07]

Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. [2010.06.17]

Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). [2010.06.11]

Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. [2010.06]

[Effect analysis on non-and-low response infants after revaccinated hepatitis B vaccine]. [2010.06]

Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. [2010.05.07]

Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. [2010.04.30]

Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders. [2010.04]

Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant Hepatitis B vaccination. [2010.03.19]

Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. [2010.03]

Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. [2010.02]

Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic. [2010.01]

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. [2010]

[Efficacy and safety of the Brazilian vaccine against hepatitis B in newborns] [2009.12]

Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. [2009.12]

Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later. [2009.10.09]

Randomized clinical trial comparing hepatitis B vaccine administered by 0, 6 and 14 week versus 6, 10 and 14 week schedule in healthy infants. [2009.10]

Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. [2009.09.18]

Prevention of hepatocellular carcinoma in hepatitis B virus infection. [2009.08]

Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. [2009.07]

Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status. [2009.06.02]

[Study on rhGM-CSF as adjuvant in revaccination among adults of non-and hyporesponders to hepatitis B vaccine] [2009.06]

Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. [2009.04.28]

Hepatitis B vaccination in haemodialysis patients: a randomized clinical trial. [2009.04]

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. [2009.03]

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. [2009.02]

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. [2009.02]

PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen. [2009.01.20]

Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults. [2009.01]

Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. [2009.01]

Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. [2008.12.02]

Immunogenicity and safety of an indigenously developed DTPw hepatitis B combination vaccine in Indian infants. [2008.10]

Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. [2008.10]

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. [2008.07.02]

Economic evaluation of delivering hepatitis B vaccine to injection drug users. [2008.07]

A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d'Ivoire. [2008.05.23]

The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. [2008.05]

Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia. [2008.05]

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. [2008.04.15]

A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. [2008.04]

Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. [2008.03.25]

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. [2008.03.04]

Positive Impact of a Shelter-based Hepatitis B Vaccine Program in Homeless Baltimore Children and Adolescents. [2008.03]

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. [2008.01.30]

Immunogenicity and safety of combined intradermal recombinant Hepatitis B with BCG vaccines at birth. [2008.01.30]

[A randomized controlled trial on effect of hepatitis B immune globulin in preventing hepatitis B virus transmission from mothers to infants] [2008.01]

One arm or two? Concurrent administration of meningococcal C conjugate and hepatitis B vaccines in pre-teens. [2008.01]

Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults. [2008.01]

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. [2007.12.12]

Comparison of accelerated and rapid schedules for monovalent hepatitis B and combined hepatitis A/B vaccines in children with cancer. [2007.12]

Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. [2007.11]

Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine. [2007.10.23]

Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant. [2007.10]

Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. [2007.10]

Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study. [2007.10]

Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure. [2007.09]

Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. [2007.09]

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. [2007.09]

Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. [2007.09]

Cellular and humoral immune response to a third generation hepatitis B vaccine. [2007.08]

[Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors] [2007.08]

Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. [2007.08]

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. [2007.08]

Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. [2007.07]

Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India. [2007.06.14]

Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. [2007.05]

Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial. [2007.04.12]

Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. [2007.04]

[Comparison of different combination therapies for children with HBeAg positive chronic hepatitis B] [2007.03]

Safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated polio vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. [2007.02.26]

Predisposing, reinforcing and enabling factors associated with hepatitis B testing in Chinese Canadians in British Columbia. [2007.01]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017